About Thomas Gadek
Form D filings for MCAL Therapeutics from 2020 to 2024 list Thomas Gadek as chief executive officer and director.
Thomas Gadek first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Thomas Gadek in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Thomas Gadek works with at each company, as listed on that company's latest Form D.
MCAL Therapeutics Inc. · Form D, Mar 27, 2024